Peptide Manufacturing Strategy Peptide CDMO vs. CMO: Which Does Your Program Actually Need? By Anusha Sinha • July 22, 2026 […]
Peptide CDMO vs. CMO: Which Does Your Program Actually Need? Read More »
Introduction Choosing a peptide Contract Development and Manufacturing Organization (CDMO) in the US requires a comprehensive assessment of technical synthesis
How to Choose a Peptide CDMO in the US: A Buyer’s Checklist Read More »
Introduction: Sponsors developing a drug for the North American market almost always end up filing in both the United States
Introduction Establishing structural equivalence through a specialized Disulfide Bond Mapping Service for Biosimilars is critical for verifying higher-order structural integrity,
Introduction Peptide API Scale-Up requires translating laboratory solid-phase synthesis into scalable, robust, and compliant current Good Manufacturing Practice (cGMP) processes
Peptide API Scale-Up: From Milligram Discovery Batches to Kilogram GMP Production Read More »
Introduction The immunogenicity of peptide-oligonucleotide conjugates is a multifaceted biological phenomenon resulting from the synergistic interplay of immunogenic peptide epitopes,
Introduction: Elemental Impurities and Residual Solvents Testing for Synthetic Peptide APIs has become one of the more scrutinized areas of
Peptide Formulation & Stability Peptide Drug Formulation Challenges: Lyophilization, Prefilled Syringes, and Injectable Stability By Anusha Sinha • July 20,
Introduction Global contract development and manufacturing organization (CDMO) capacity is under severe pressure because the unprecedented multi-ton demand for semaglutide
Introduction Developing therapeutic peptides within a regulated environment requires selecting a synthetic strategy that effectively balances chemical scalability with stringent
